Clinical Research- New Updates!
The Gastric Stimulator Device is listed under clinical research due to the FDA and how they have approved this device. No research data is collected on patients.
Patients diagnosed with gastroparesis may be eligible for device placement. This device is used for patients with medically refractory nausea and vomiting. After device placement, patients follow up in the clinical on a standard of care basis.
New Medicinal Therapy for Gastroparesis Patients
New Therapeutic Study Opening December 2017
Screening and enrollment will begin shortly. This study is designed for Diabetic Gastroparesis patients suffering from nausea and vomiting.
If you would like more information, please contact Sierra (research coordinator) at 720-508-8855 or [email protected]
A special thank you to all of our patients that participated in the Phase 2b Theravance Biopharma study of Velusetrag. We are excited to share the early results from this study: